When the COVID-19 pandemic first began, we saw how quickly the SARS-CoV-2 virus evolved. New variants emerged with mutations ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors.

The virus that causes COVID-19 has been very good at mutating to keep infecting people—so good that most antibody treatments ...

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

A team has found two antibodies that can work together to neutralize the virus that causes COVID-19 in all its current known variations in a laboratory environment. More research is needed, but the ...

Viruses like the one that causes COVID-19 constantly mutate, rendering many antibody treatments ineffective. A Stanford-led ...

The following is a summary of “A systematic review and meta-analysis of the effectiveness of remdesivir to treat SARS-CoV-2 ...

Most notoriously, SARS-CoV-2 jumped a huge evolutionary hurdle to spawn the omicron variant, which spread around the world with shocking speed. And the pace of the virus's evolution hasn't changed ...

Centers for Disease Control reports LP.8.1, XEC and KP.3.1.1 together constitute the majority of current national SARS-CoV-2 variants; current dominant variants are all susceptible to PEMGARDA ...

PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1, KP.3.1.1, XEC, and LP.8.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor ...

XEC currently represents about half of all Covid infections, but LP. 8.1 is quickly gaining ground, accounting for ...

March 05, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA™ (pemivibart) against the currently ...